Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: <i>post hoc</i> subanalysis of the randomized, phase 3 PROPEL study.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: C.E.-E. has received grant/research support from Biotest, CSL Behring, Octapharma, Shire (a Takeda company), and Sobi; honoraria for lectures/advisory boards from Bayer, Biotest, CSL Behring, Grifols, Kedrion, Novo Nordisk, Octapharma, Pfizer, Roche/Chugai, Shire (a Takeda company), and Sobi; and consultancy fees from BioMarin, Biotest, CSL Behring, Grifols, Novo Nordisk, Octapharma, Roche/Chugai, Shire (a Takeda company), and Sobi. R.K. has received grant/research support from Bayer, BioMarin, CSL Behring, Novo Nordisk, Octapharma, Pfizer, and Shire (a Takeda company); consultancy fees from Bayer, BioMarin, Biotest, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, Shire (a Takeda company), and Sobi; and speaker bureau fees from Bayer, BioMarin, Biotest, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, Shire (a Takeda company), and Sobi. M.E. has received grant/research support from Genentech, Novo Nordisk, Sanofi, Takeda, and uniQure; and consultancy fees from Bayer, BioMarin, CSL Behring, FDA, Genentech/Roche, Kedrion, Novo Nordisk, Pfizer, Sanofi, and Shire (a Takeda company). O.S. is an employee of the Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine; and has received grant/research support from CSL Behring, Novo Nordisk, Sanofi, Shire (a Takeda company), and Pfizer; and speaker bureau fees from LFB, Novo Nordisk, Octapharma, Pfizer, Roche, and Shire (a Takeda company). S.T. is an employee of Takeda Development Center Americas, Inc. and a Takeda stock owner. At the time of the study, W.E. was an employee of Baxalta Innovations GmbH, a Takeda company and was a Takeda stock owner. At the time of the study, I.H. was an employee of Baxalta GmbH, a Takeda company, and was a Takeda stock owner. H.-Y.L is an employee of Baxalta GmbH, a Takeda company, and is a Takeda stock owner. P.C. is on the advisory boards of Bayer, Boehringer Ingelheim, Chugai, CSL Behring, Freeline, Novo Nordisk, Pfizer, Roche, Sanofi, Sobi, Spark, and Takeda; and has received grant/research support from Bayer, CSL Behring, Freeline, Novo Nordisk, Pfizer, Sobi, and Takeda. J.W. has received grant/research support and honoraria for lectures from Alexion, Alnylam, Baxalta/Shire (a Takeda company), Bayer, CSL Behring, Ferring, Novo Nordisk, Octapharma, Rigel, Roche, Sanofi, Siemens, Sobi, and Werfen."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by research funding from Baxalta US Inc, a Takeda company, Lexington, MA, USA, and Baxalta Innovations GmbH, a Takeda company, Vienna, Austria."

"Registration:: ClinicalTrials.gov Identifier: NCT02585960; https://clinicaltrials.gov/ct2/show/NCT02585960"